Abstract
CYP2C19 is a clinically important enzyme involved in the metabolism of therapeutic drugs such as (S)-mephenytoin, omeprazole, proguanil, and diazepam. Individuals can be characterized as either extensive metabolizers (EM) or poor metabolizers (PM) on the basis of CYP2C19 enzyme activity. The PM phenotype occurs in 2–5% of Caucasian populations, but at higher frequencies (18–23%) in Asians. CYP2C19*2 and CYP2C19*3, which are single-nucleotide polymorphisms of CYP2C19, are the main cause of PM phenotyping in homozygotes or compound heterozygotes. We report two novel mutations in the CYP2C19 gene identified by direct sequencing and subcloning procedures. One of these mutations was considered to be CYP2C19*3 by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). This result suggests that mutations classed as CYP2C19*3 might include other mutations. Further studies are needed to clarify the relationship between these novel mutations and enzyme activity.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Adedoyin A, Prakash C, O’Shea D, Blair IA, Wilkinson GR (1994) Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 4:27–38
Andersson T, Regardh C, Lou Y, Zhang Y, Dahl M, Bertilsson L (1992) Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2:25–31
Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin , but, not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348–355
Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12:703–711
De Morais SMF, Wilkinson GR, Blaisdell J, Mayer UA, Nakamura K, Goldstein JA (1994a) Identification of new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598
De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994b) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419–15422
Ferguson RJ, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356–361
Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the humanCYP2C sybfamily. Br J Clin Pharmacol 52:349–355
Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743–1752
Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J (1998a) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286:1490–1495
Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA, Daly AK (1998b) An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizers phenotype in Caucasians. Pharmacogenetics 8:129–135
Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290:635–640
Inaba T, Jurima M, Kalow W (1986) Family studies of mephenytoin hydroxylationdeficiency. Am J Hum Genet 38:768–772
Itoh K, Inoue K, Yanagiwara S, Kyoya H, Suzuki T (1999) A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. Bio Pharm Bull 22:77–79
Kawamura M, Ohara S, Koike T, Iijima K, Suzuki L, Kayaba S, Noguchi K, Hamada S, Noguchi M, Shimosegawa T (2003) The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17:965–973
Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661–666
Kupfer A, Branch RA (1985) Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 38:414–418
Kupher A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753–759
Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402–408
Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinaki J, Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 323:87–96
Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450 2C subfamily. Biochemistry 30:3247–3255
Sindrup SH, Brosen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF, Gram LF (1993) Pharmacokinetics of citalopram in relation to the spartein and the mephenytoin oxidation polymorphisms. Ther Drug Monit 13:11–17
Skjelbo E, Broswn K, Hallas J, Gram LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49:18–23
Ward SA, Goto F, Nakamura K, Jacqz E, Wilkinson GR, Branch RA (1987) S-mephenytoin 4-hydroxylase is inherited as an autosomal recessive trait in Japanese families. Clin Pharmacol Ther 42:96–99
Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA (1989) Propranolol’s metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 45:72–79
Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism a panel study. Br J Clin Pharmacol 31:689–692
Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773–780
Wilkinsin GR, Guengerrich FP, Branch RA (1989) Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53–76
Wrighton SA, Stevens JC, Becker GW, VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306:240–245
Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang Yan FX, He N, Huang SL, Xu ZH, Zhou HH (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai popilations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281:604–609
Author information
Authors and Affiliations
Corresponding author
Additional information
The DDBJ accession number of the novel mutation is AB113829
Rights and permissions
About this article
Cite this article
Ohkubo, Y., Ueta, A., Ando, N. et al. Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation. J Hum Genet 51, 118–123 (2006). https://doi.org/10.1007/s10038-005-0332-y
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-005-0332-y
